Lucid Diagnostics (NASDAQ:LUCD) Given New $2.00 Price Target at Cantor Fitzgerald

Lucid Diagnostics (NASDAQ:LUCD) had its price objective decreased by Cantor Fitzgerald from $3.00 to $2.00 in a research report sent to investors on Friday morning,Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the stock.

LUCD has been the topic of several other reports. Ascendiant Capital Markets dropped their price objective on Lucid Diagnostics from $7.50 to $7.25 and set a “buy” rating on the stock in a report on Tuesday, September 10th. Canaccord Genuity Group restated a “buy” rating and set a $3.00 price objective on shares of Lucid Diagnostics in a report on Thursday. Needham & Company LLC restated a “buy” rating and set a $2.50 price objective on shares of Lucid Diagnostics in a report on Thursday. Finally, Canaccord Genuity Group upgraded Lucid Diagnostics to a “strong-buy” rating in a report on Tuesday, August 13th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $3.69.

Lucid Diagnostics Stock Performance

Shares of NASDAQ:LUCD opened at $0.99 on Friday. The company has a market cap of $58.56 million, a P/E ratio of -0.87 and a beta of 1.41. Lucid Diagnostics has a one year low of $0.63 and a one year high of $1.58. The business’s 50-day simple moving average is $0.87 and its 200 day simple moving average is $0.85.

Institutional Investors Weigh In On Lucid Diagnostics

An institutional investor recently raised its position in Lucid Diagnostics stock. Virtu Financial LLC grew its position in Lucid Diagnostics Inc. (NASDAQ:LUCD) by 66.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 34,671 shares of the company’s stock after acquiring an additional 13,835 shares during the quarter. Virtu Financial LLC owned approximately 0.07% of Lucid Diagnostics worth $28,000 as of its most recent filing with the Securities and Exchange Commission. 74.01% of the stock is currently owned by institutional investors and hedge funds.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.